Featured Research

from universities, journals, and other organizations

New Approach Supercharges Immunotherapy

Date:
December 10, 1998
Source:
University Of Chicago Medical Center
Summary:
By tripping two parallel "on switches" at once, instead of the customary single switch, physicians at the University of Chicago Medical Center may at last have found a way to bring the full power of the immune system into play against cancer. Early results from the first clinical trial of this approach will be presented December 5th at the American Society of Hematology annual meeting in Miami Beach, Florida.

Co-stimulation activates T cells against resistant lymphomas

By tripping two parallel "on switches" at once, instead of the customary single switch, physicians at the University of Chicago Medical Center may at last have found a way to bring the full power of the immune system into play against cancer. Early results from the first clinical trial of this approach will be presented December 5th at the American Society of Hematology annual meeting in Miami Beach, Florida.

This phase-1 clinical trial -- designed not to assess effectiveness but to determine the optimal dose and measure toxicity -- involved patients with advanced or recurrent lymphoma who had not responded to prior chemotherapy. Although patients in phase-1 studies like this rarely have a lasting recovery, several of those enrolled in this trial have experienced noteworthy anti-tumor effects.

"When you consider that none of these patients had responded to any other therapy, you can begin to understand our enthusiasm," said David Liebowitz, M.D., Ph.D., director of stem-cell transplantation at the University of Chicago and principal investigator of the study. "Although this is a complex and difficult treatment regimen, all the early signs suggest that it can be a uniquely effective one."

The treatment is based on recent recognition of the importance of "co-stimulation" in triggering an immune response. Previous efforts to activate the immune system have relied on stimulation of a single signaling system, the T-cell receptor for antigen, known as CD3, a cell-surface molecule that recognizes foreign tissue.

Nearly ten years ago, however, Chicago researchers Craig Thompson and Jeffrey Bluestone and others discovered that the immune system often requires two parallel lines of communication -- through both CD3 and a second receptor, known as CD28 -- before girding for battle. Stimulation of both CD3 and CD28 triggers an aggressive immune response; tweaking only CD3 produces little or no response.

"This discovery addresses the basic question facing cancer immunotherapy," said Liebowitz: "Why are the T cells that should attack tumors content to sit idly by? Previous efforts to jump start an immune response have not been able effectively to reverse the immune tolerance that develops between a patient's T cells and their cancer."

But by growing billions of a patient's T cells in the laboratory, away from tumor cells and under constant co-stimulation with CD3 and CD28, Liebowitz's team has been able to reactivate the immune response, returning a population of aggressive, "motivated" cells to seek out and attack cancerous cells.

"Co-stimulation gives us a completely different population of T cells," said Liebowitz. Prior attempts have produced large numbers of cytotoxic T cells, which are the end product of an immune response. Growth in the presence of CD3 and CD28, however, produces primarily T-helper cells, so called because they coordinate the actions of the entire immune system."

This is the only system currently in use that favors the growth of T-helper cells over cytotoxic cells.

A few weeks after receiving their new, improved T-helper cells, some patients have experienced fevers and lethargy while their T-cell counts continue to rise. Over the following weeks and months, much too slowly to be a late response to prior chemotherapy, their tumors get smaller and in some cases have disappeared.

"We know we are affecting the immune response with this therapy because the toxicities we have seen after reinfusion look exactly like autoimmune disorders," (in which an over-aggressive immune system attacks its host) said Liebowitz.

Although the side effects of reinfusing the rejuvenated T cells appear to be limited, the entire treatment protocol is quite rigorous. Treatment involves collecting and storing stem cells from the patient's blood, administering high-dose chemotherapy which destroys the bone marrow, then giving the patient his stem cells back to repopulate the marrow. Fourteen days later, the patients receive their expanded, co-stimulated T cells.

So far the team has enrolled nearly 20 patients. Some are still receiving therapy. Because of advanced disease, rapid progression of the cancer during therapy, or the difficulties of harvesting and growing T cells, only eight patients have so far received their expanded T cells.

Six of those eight patients have had what appear to be complete remissions, but it remains unclear how long they will last. After an average of 305 days, two of those patients had relapsed. The recurrent disease "in some cases," said Liebowitz "appears to be less aggressive."

"We canΉt claim to have cured anyone," added Liebowitz, "but we seem to have altered the natural history of the disease, to have significantly slowed progression in selected patients."

The co-stimulation technology, which uses tiny magnetic beads covered with monoclonal antibodies to CD3 and CD28, was developed and patented by Thompson at the University of Chicago and Dr. Carl June at the Uniformed Services University of the Health Sciences. The University of Chicago's ARCH Development Corporation has licensed the technology for development to a start-up company called Xcyte Therapies, based in Seattle. Thompson, Bluestone and June are founding scientists at the company.


Story Source:

The above story is based on materials provided by University Of Chicago Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Chicago Medical Center. "New Approach Supercharges Immunotherapy." ScienceDaily. ScienceDaily, 10 December 1998. <www.sciencedaily.com/releases/1998/12/981210082339.htm>.
University Of Chicago Medical Center. (1998, December 10). New Approach Supercharges Immunotherapy. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/1998/12/981210082339.htm
University Of Chicago Medical Center. "New Approach Supercharges Immunotherapy." ScienceDaily. www.sciencedaily.com/releases/1998/12/981210082339.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) — Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Peace Corps Pulls Workers From W. Africa Over Ebola Fears

Newsy (July 30, 2014) — The Peace Corps is one of several U.S.-based organizations to pull workers out of West Africa because of the Ebola outbreak. Video provided by Newsy
Powered by NewsLook.com
Weather Kills 2K A Year, But Storms Aren't The Main Offender

Weather Kills 2K A Year, But Storms Aren't The Main Offender

Newsy (July 30, 2014) — Health officials say 2,000 deaths occur each year in the U.S. due to weather, but it's excessive heat and cold that claim the most lives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins